Samsung Pharmaceutical Co., Ltd. (KOSE:A001360) agreed to sell 17.13% stake in Medizen Humancare Co.,Ltd. for KRW 2 billion on September 1, 2015. The Board of Directors of Samsung Pharmaceutical passed a resolution for the transaction on September 1, 2015. The transaction is expected to close on October 8, 2015.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4,950 KRW | -2.56% | -4.44% | +23.75% |
1st Jan change | Capi. | |
---|---|---|
+23.75% | 8.37M | |
-27.80% | 9.88B | |
+28.35% | 2.89B | |
-15.08% | 2.88B | |
-15.73% | 2.12B | |
-20.79% | 1.67B | |
+70.99% | 1.45B | |
+28.75% | 788M | |
-4.15% | 741M | |
-28.88% | 514M |
- Stock Market
- Equities
- A236340 Stock
- News MEDIZEN HUMANCARE Inc.
- Samsung Pharmaceutical Co., Ltd. agreed to sell 17.13% stake in Medizen Humancare Co.,Ltd. for KRW 2 billion.